Vol 4, No 3 (September 11, 2013): Journal of Gastrointestinal Oncology

Editorial

Targeted therapies in colorectal cancer: the dos, don’ts, and future directions
Marwan Fakih
Journal of Gastrointestinal Oncology  
2013;
4
(3)
:239-244
.

Review Articles

Status of targeted therapies in the adjuvant treatment of colon cancer
Valerie M. Nelson, Al B. Benson III
Journal of Gastrointestinal Oncology  
2013;
4
(3)
:245-252
.
Understanding and targeting resistance to anti-angiogenic therapies
Jeffrey M. Clarke, Herbert I. Hurwitz
Journal of Gastrointestinal Oncology  
2013;
4
(3)
:253-263
.
The status of targeted agents in the setting of neoadjuvant radiation therapy in locally advanced rectal cancers
Rob Glynne-Jones, Maher Hadaki, Mark Harrison
Journal of Gastrointestinal Oncology  
2013;
4
(3)
:264-284
.
Integrating anti-EGFR therapies in metastatic colorectal cancer
Sigurdis Haraldsdottir, Tanios Bekaii-Saab
Journal of Gastrointestinal Oncology  
2013;
4
(3)
:285-298
.
Continuum of care with anti-angiogenic therapies in metastatic colorectal cancer
Brandon G. Smaglo, Jimmy Hwang
Journal of Gastrointestinal Oncology  
2013;
4
(3)
:299-307
.
Markers of resistance to anti-EGFR therapy in colorectal cancer
Walid Shaib, Reena Mahajan, Bassel El-Rayes
Journal of Gastrointestinal Oncology  
2013;
4
(3)
:308-318
.
A review of cutaneous toxicities from targeted therapies in the treatment of colorectal cancers
Christopher Urban, Milan J. Anadkat
Journal of Gastrointestinal Oncology  
2013;
4
(3)
:319-327
.
Targeted therapies in colorectal cancer: surgical considerations
Carrie Luu, Amanda K. Arrington, Hans F. Schoellhammer, Gagandeep Singh, Joseph Kim
Journal of Gastrointestinal Oncology  
2013;
4
(3)
:328-336
.